Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, Negri E, et al. European most cancers mortality predictions for the 12 months 2020 with a concentrate on prostate most cancers. Ann Oncol. 2020;31:650–8.
Hamid AA, Sayegh N, Tombal B, Hussain M, Sweeney CJ, Graff JN, et al. Metastatic hormone-sensitive prostate most cancers: towards an period of adaptive and customized remedy. Am Soc Clin Oncol Educ E book. 2023;43:e390166.
Ferretti S, Mercinelli C, Marandino L, Litterio G, Marchioni M, Schips L. Metastatic castration-resistant prostate most cancers: insights on present remedy and promising experimental medicine. Res Rep Urol. 2023;15:243–59.
Berruti A, Bracarda S, Caffo O, Cortesi E, D’Angelillo R, Del Re M, et al. nmCRPC, a glance within the steady care of prostate most cancers sufferers: state of artwork and future views. Most cancers Deal with Rev. 2023;115:102525.
Scher HI, Fizazi Okay, Saad F, Taplin ME, Sternberg CN, Miller Okay, et al. Elevated survival with enzalutamide in prostate most cancers after chemotherapy. N Engl J Med. 2012;367:1187–97.
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate most cancers earlier than chemotherapy. N Engl J Med. 2014;371:424–33.
Sternberg CN, Fizazi Okay, Saad F, Shore ND, De Giorgi U, Penson DF, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate most cancers. N Engl J Med. 2020;382:2197–206.
Hussain M, Fizazi Okay, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in males with nonmetastatic, castration-resistant prostate most cancers. N Engl J Med. 2018;378:2465–74.
Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, part III examine of androgen deprivation remedy with enzalutamide or placebo in males with metastatic hormone-sensitive prostate most cancers. J Clin Oncol. 2019;37:2974–86.
Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus normal antiandrogen remedy for metastatic hormone-sensitive prostate most cancers (ENZAMET): a world, open-label, randomised, part 3 trial. Lancet Oncol. 2023;24:323–34.
Web page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 assertion: an up to date guideline for reporting systematic evaluations. Bmj. 2021;372:n71.
Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate most cancers. N Engl J Med. 2023;389:1453–65.
Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or with out enzalutamide for high-risk non-metastatic prostate most cancers: a meta-analysis of major outcomes from two randomised managed part 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399:447–60.
Kaplan I, Bubley GJ, Bhatt RS, Taplin ME, Dowling S, Mahoney Okay, et al. Enzalutamide with radiation remedy for intermediate-risk prostate most cancers: a part 2 examine. Int J Radiat Oncol Biol Phys. 2021;110:1416–22.
Lara PC, Rodríguez-Melcón JI, Palacios-Eito A, Lozano A, Hervás-Morón A, Villafranca E, et al. Section II examine of ENZAlutamide mixed with hypofractionated radiation remedy (ENZART) for localized intermediate threat prostate most cancers. Entrance Oncol. 2022;12:891886.
McKay RR, Ye H, Xie W, Lis R, Calagua C, Zhang Z, et al. Analysis of intense androgen deprivation earlier than prostatectomy: a randomized part II trial of enzalutamide and leuprolide with or with out abiraterone. J Clin Oncol. 2019;37:923–31.
Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, et al. Neoadjuvant enzalutamide previous to prostatectomy. Clin Most cancers Res. 2017;23:2169–76.
Shee Okay, de la Calle CM, Chang AJ, Wong AC, Feng FY, Gottschalk AR, et al. Addition of enzalutamide to leuprolide and definitive radiation remedy is tolerable and efficient in high-risk localized or regional nonmetastatic prostate most cancers: outcomes from a part 2 trial. Adv Radiat Oncol. 2022;7:100941.
Shore ND, Renzulli J, Fleshner NE, Hollowell CMP, Vourganti S, Silberstein J, et al. Enzalutamide monotherapy vs energetic surveillance in sufferers with low-risk or intermediate-risk localized prostate most cancers: the ENACT randomized medical trial. JAMA Oncol. 2022;8:1128–36.
Bitting RL, Healy P, George DJ, Anand M, Kim S, Mayer T, et al. Section II trial of enzalutamide and androgen deprivation remedy with salvage radiation in males with high-risk prostate-specific antigen recurrent prostate most cancers: the STREAM trial. Eur Urol Oncol. 2021;4:948–54.
Madan RA, Karzai F, Donahue RN, Al-Harthy M, Bilusic M, Rosner II, et al. Medical and immunologic influence of short-course enzalutamide alone and with immunotherapy in non-metastatic castration delicate prostate most cancers. J Immunother Most cancers. 2021;9:e001556.
Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, et al. Lengthy-term antitumor exercise and security of enzalutamide monotherapy in hormone Naïve prostate most cancers: 3-year open label followup outcomes. J Urol. 2018;199:459–64.
Tran PT, Lowe Okay, Tsai HL, Tune DY, Hung AY, Hearn JWD, et al. Section II randomized examine of salvage radiation remedy plus enzalutamide or placebo for high-risk prostate-specific antigen recurrent prostate most cancers after radical prostatectomy: the SALV-ENZA trial. J Clin Oncol. 2023;41:1307–17.
Mottet NCP, van den Bergh RCN, et al. EAU tips 2023 [Available from: https://uroweb.org/guidelines/prostate-cancer/chapter/treatment.
Gómez Rivas J, Gandaglia G, Montorsi F. Re: Neal D. Shore, Joseph Renzulli, N E. Fleshner, et al. Active Surveillance plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128-36: Let’s Not Go Back in Time! What Have We Learned in the Treatment of Localized Prostate Cancer? Applicability of the ENACT Randomized Clinical Trial in Clinical Practice. Eur Urol Open Sci. 2022;46:135–6.
Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ Jr, Yossepowitch O, Vickers AJ, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol. 2009;27:4300–5.
Liu W, Yao Y, Liu X, Liu Y, Zhang GM. Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis. Asian J Androl. 2021;23:429–36.
Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev. 2006;2006:Cd006019.
Krauss DJ, Karrison T, Martinez AA, Morton G, Yan D, Bruner DW, et al. Dose-escalated radiotherapy alone or in combination with short-term androgen deprivation for intermediate-risk prostate cancer: results of a phase III multi-institutional trial. J Clin Oncol. 2023;41:3203–16.
Bolla M, Maingon P, Carrie C, Villa S, Kitsios P, Poortmans PM, et al. Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991. J Clin Oncol. 2016;34:1748–56.
Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011;365:107–18.
Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer. 2009;115:2388–99.
Roy S, Romero T, Michalski JM, Feng FY, Efstathiou JA, Lawton CAF, et al. Biochemical recurrence surrogacy for clinical outcomes after radiotherapy for adenocarcinoma of the prostate. J Clin Oncol. 2023;41:5005–14.
Tree A, Griffin C, Syndikus I, Birtle A, Choudhury A, Graham J, et al. Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) analogs in combination with radiation therapy in the CHHiP trial. Int J Radiat Oncol Biol Phys. 2022;113:305–15.
Schmidt-Hegemann N-S, Zamboglou C, Mason M, Mottet N, Hinnen K, De Meerleer G, et al. ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer. Radiother Oncol. 2023;183:109544.
Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022;399:1886–901.
Carrie C, Magne N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange JL, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019;20:1740–9.
Parker CC, Clarke N, Cook A, Catton C, Cross WR, Kynaston H, et al. LBA9 Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: first results of the RADICALS-HD trial (ISRCTN40814031). Ann Oncol. 2022;33:S1427.
Burdett S, Fisher D, Parker CC, Sydes MR, Pommier P, Sargos P, et al. LBA64 Duration of androgen suppression with post-operative radiotherapy (DADSPORT): A collaborative meta-analysis of aggregate data. Ann Oncol. 2022;33:S1428–S9.
Dess RT, Sun Y, Jackson WC, Jairath NK, Kishan AU, Wallington DG, et al. Association of presalvage radiotherapy PSA levels after prostatectomy with outcomes of long-term antiandrogen therapy in men with prostate cancer. JAMA Oncol. 2020;6:735–43.
Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376:417–28.
Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, et al. Long-term efficacy and safety of enzalutamide monotherapy in hormone-naïve prostate cancer: 1- and 2-year open-label follow-up results. Eur Urol. 2015;68:787–94.
Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, et al. Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. Lancet Oncol. 2014;15:592–600.
Freedland SJ, De Giorgi U, Gleave M, Rosbrook B, Shen Q, Sugg J, et al. A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design. BMJ Open. 2021;11:e046588.
Eissa A, Elsherbiny A, Coelho RF, Rassweiler J, Davis JW, Porpiglia F, et al. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature. Minerva Urol Nefrol. 2018;70:462–78.
